Literature DB >> 20964565

Comparison of the efficacy of 5% topical spironolactone gel and placebo in the treatment of mild and moderate acne vulgaris: a randomized controlled trial.

Bahare Malek Afzali1, Elena Yaghoobi, Reza Yaghoobi, Nooshin Bagherani, Mohammad Ali Dabbagh.   

Abstract

BACKGROUND: Topical spironolactone may be effective for the treatment of acne patients with increased sebum secretion.
OBJECTIVE: To evaluate the efficacy of 5% spironolactone gel in the treatment of mild to moderate acne vulgaris.
METHODS: This study was a double-blind clinical trial, performed randomly in two demographically equivalent groups. In this study, 78 patients with mild to moderate acne vulgaris participated. The patients, as groups of cases (38 patients) and controls (40 patients), took 5% spironolactone gel and placebo, respectively. The response to treatment was evaluated by the total acne lesions (TLC) and acne severity index (ASI).
RESULTS: The mean age of the case patients was 21.5 ± 4.2 years and of the control patients was 22.2 ± 4.06 years. The difference in TLC was statistically significant between the two groups (p = 0.007), but no statistically significant difference was seen between the two groups for ASI (p = 0.052).
CONCLUSION: The 5% spironolactone topical gel resulted in a decrease in the TLC in acne vulgaris, while it had no significant efficacy in the ASI.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20964565     DOI: 10.3109/09546634.2010.488260

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN: 0954-6634            Impact factor:   3.359


  10 in total

Review 1.  Androgen Receptor Inhibitors in the Treatment of Acne Vulgaris: Efficacy and Safety Profiles of Clascoterone 1% Cream.

Authors:  Carol Sanchez; Jonette Keri
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-07-15

Review 2.  A Review of hormone-based therapies to treat adult acne vulgaris in women.

Authors:  M K Trivedi; K Shinkai; J E Murase
Journal:  Int J Womens Dermatol       Date:  2017-03-30

Review 3.  Comparative Efficacy of Pharmacological and Nonpharmacological Interventions for Acne Vulgaris: A Network Meta-Analysis.

Authors:  Qingyang Shi; Lizi Tan; Zhe Chen; Long Ge; Xiaoyan Zhang; Fengwen Yang; Chunxiang Liu; Junhua Zhang
Journal:  Front Pharmacol       Date:  2020-11-26       Impact factor: 5.810

4.  The Effects of Myrtle (Myrtus communis) and Clindamycin Topical Solution in the Treatment of Mild to Moderate Acne Vulgaris: A Comparative Split-Face Study.

Authors:  Mahboobeh Salmanian; Laila Shirbeigi; Fataneh Hashem-Dabaghian; Parvin Mansouri; Mohammad Azizkhani; Shiva Alavi; Ali Ghobadi
Journal:  J Pharmacopuncture       Date:  2020-12-31

Review 5.  Optimizing Non-Antibiotic Treatments for Patients with Acne: A Review.

Authors:  Theresa N Canavan; Edward Chen; Boni E Elewski
Journal:  Dermatol Ther (Heidelb)       Date:  2016-08-19

6.  Spironolactone for the treatment of acne in women, a retrospective study of 110 patients.

Authors:  J W Charny; J K Choi; W D James
Journal:  Int J Womens Dermatol       Date:  2017-03-13

Review 7.  Spironolactone and XPB: An Old Drug with a New Molecular Target.

Authors:  Ryan D Gabbard; Robert R Hoopes; Michael G Kemp
Journal:  Biomolecules       Date:  2020-05-13

8.  Spironolactone-Loaded LeciPlexes as Potential Topical Delivery Systems for Female Acne: In Vitro Appraisal and Ex Vivo Skin Permeability Studies.

Authors:  Ayman Salama; Mohamed Badran; Mohammed Elmowafy; Ghareb M Soliman
Journal:  Pharmaceutics       Date:  2019-12-25       Impact factor: 6.321

9.  Spironolactone hyaluronic acid enriched cerosomes (HAECs) for topical management of hirsutism: in silico studies, statistical optimization, ex vivo, and in vivo studies.

Authors:  Rofida Albash; Abdurrahman M Fahmy; Mohammed I A Hamed; Khaled M Darwish; Rania Moataz El-Dahmy
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

10.  Efficacy and safety of topical spironolactone 5% cream in the treatment of acne: A pilot study.

Authors:  Azin Ayatollahi; Ansieh Samadi; Ayda Bahmanjahromi; Reza M Robati
Journal:  Health Sci Rep       Date:  2021-07-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.